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Background: The emergence of IL-33 as a key molecular player in the development 44 
and propagation of widespread inflammatory diseases including asthma and atopic 45 
dermatitis has established the need for effective IL-33 neutralizing biologics.  46 
Objective: Here we describe the development and validation of a new antagonist of 47 
IL-33, termed IL-33trap, which combines the extracellular domains of the IL-33 48 
receptor (ST2) and its co-receptor IL-1 receptor accessory protein, into a single 49 
fusion protein.   50 
Methods: We produced and purified recombinant IL-33trap from human cells and 51 
analyzed its IL-33 binding affinity and IL-33 antagonistic activity in cultured cells and 52 
in mice. IL-33trap activity was also benchmarked with a recombinant soluble ST2 53 
(sST2) corresponding to the naturally occurring IL-33 decoy receptor. Finally, we 54 
studied the effect of IL-33trap in the Alternaria alternata mouse model of allergic 55 
airway inflammation.  56 
Results: In vitro, IL-33trap binds IL-33 and inhibits IL-33 activity much stronger than 57 
sST2. Furthermore, IL-33trap inhibits eosinophil infiltration, splenomegaly, and the 58 
production of signature cytokines in splenic lymphocytes and lung tissue upon IL-33 59 
injection. Finally, administration of IL-33trap at the time of allergen challenge inhibits 60 
inflammatory responses in a preclinical mouse model of acute allergic airway 61 
inflammation.  62 
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Conclusions: IL-33trap is a novel IL-33 antagonist that outperforms the natural IL-33 63 
decoy receptor and shows anti-inflammatory activities in a preclinical mouse model of 64 
acute allergic airway inflammation when given at the time of allergen challenge.  65 
Clinical implications 66 
IL-33trap may be an interesting lead towards the development of novel approaches 67 















Capsule summary 81 
IL-33 is an important therapeutic target in allergic diseases. Here we describe the 82 
generation and biological activity of a novel IL-33 antagonist, IL-33trap, which shows 83 
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Allergic diseases such as allergic asthma are chronic inflammatory conditions that 120 
remain a serious health problem. The prevalence of asthma has been rising since the 121 
last part of the 20th century and 15% or more of the general population in many 122 
countries suffer from this disease.1 In general, treatment of asthma is well 123 
established and is dominated by inhaled corticosteroids and long-acting β2-agonists. 124 
However, about 5% of asthma patients are believed to achieve poor control of their 125 
asthma using existing treatments. Moreover, long-term treatment with corticosteroids 126 
suffers from side effects. Antibodies targeting several key molecular mediators of 127 
type 2 immunity have recently been launched or are being developed. Omalizumab, 128 
targeting IgE, has been the only biologic indicated for treatment of asthma for over a 129 
decade. However, very recently two IL-5 targeting antibodies, mepolizumab and 130 
reslizumab and an antibody targeting the IL-5 receptor (benralizumab) have been 131 
approved for the treatment of severe asthma. Also antisense molecule-based 132 
therapies that target key proteins by inactivating the corresponding RNA have shown 133 
much promise in early clinical trials. However, in vivo stability of these therapeutics, 134 
adverse side-effects and delivery routes still remain important challenges for the 135 
future.2 136 
Asthma is a complex and heterogeneous disease, and currently available biologics 137 
are forecasted to cover only part of the patients, indicating there is still a need for 138 
other medications. Novel innovative cytokine targeting therapies with biologics on 139 
carefully selected populations of patients, personalized on the basis of their specific 140 
disease sub-phenotype (identified by discriminatory biomarkers and genetic profiling) 141 
are expected to lead to significant advances in the field of asthma treatment.3 One of 142 
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the key players in allergic inflammation is interleukin-33 (IL-33), which belongs to the 143 
IL-1 superfamily of cytokines that drive the initiation of inflammatory responses.4 Next 144 
to asthma, IL-33 has also been implicated in other allergic diseases such as atopic 145 
dermatitis,4 allergic rhinitis5 and food allergy.6 IL-33 is primarily known as an alarmin 146 
that is released from epithelial barrier cells upon exposure to allergens or other stress 147 
factors,7, 8 and mainly activates innate lymphoid cells type 2 (ILC2) and Th2 148 
lymphocyte effector cells.9, 10  The fact that IL-33 acts upstream of Th2-associated 149 
cytokines and IgE production, makes IL-33 an enticing target for biologics against 150 
type 2 immunity related diseases. Depending on the cellular context, IL-33 can also 151 
affect Th1 cells, mast cells, macrophages, dendritic cells, fibroblasts and regulatory T 152 
cells, which play key roles in various pathological conditions.4  153 
Extracellular IL-33 coordinates an immune response by binding to a receptor 154 
complex consisting of IL-1 receptor-like 1 (IL-1RL1) (better known as ST2) and IL-1 155 
receptor accessory protein (IL-1RAcP), followed by the initiation of several signaling 156 
pathways culminating in the activation of specific gene expression and release of pro-157 
inflammatory cytokines.11 IL-33 activity is limited by a decoy receptor, an alternative 158 
splice variant of ST2 coding for a soluble extracellular portion of the receptor, known 159 
as soluble ST2 (sST2).12,13 Both IL-33 and ST2 have been identified as major 160 
susceptibility loci in genome-wide association studies of human asthma.14 Moreover, 161 
IL-33 is upregulated in asthma patients,15, 16 with increased levels of extracellular IL-162 
33 being associated with asthma disease exacerbation.17 Noteworthy, previous 163 
studies indicate that lung IL-33 expression and release is resistant to steroid 164 
treatment,18, 19 suggesting that IL-33 targeting therapeutics may be particularly 165 
beneficial in a population of steroid-resistant asthmatics.  166 
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Supporting the therapeutic potential of IL-33 inhibition, several genetic (IL-33 and 167 
ST2 knockout mice) and pharmacological strategies (antibodies targeting IL-33 or 168 
ST2, or use of recombinant sST2) to interfere with IL-33/ST2 signaling have shown 169 
beneficial effects in preclinical mouse models of allergic asthma.4 Here we report the 170 
generation and characterization of a novel sST2-based biologic that exhibits greatly 171 
enhanced binding affinity to IL-33 compared to normal cellular sST2 and functions as 172 





















Antibodies, expression plasmids and other reagents 192 
V450-labeled antibody to mouse CD11b, PE-labeled antibody against Siglec-F, 193 
AF700-labeled antibody to Ly6G, FITC-labeled antibodies to B220, CD8a and 194 
CD11c, BV786-labeled antibody to streptavidin and PE-CF594-labeled antibody to 195 
CD127 were purchased from BD Biosciences. PE-Cy5– or FITC-labeled antibodies to 196 
CD3 and CD19 were purchased from VWR. BV605-labeled antibody to CD90.2 was 197 
purchased from BioLegend. Biotin-labeled antibody to ST2 was purchased from MD 198 
Bioproducts. PE-Cy7-labeled antibody to CD25 was from LifeTechnologies. FITC-199 
labeled antibodies to MHCII, NK1.1, Ter-119 and CD4, PE-labeled antibody to 200 
FoxP3, PE-Cy5-labeled antibody to CD19, APC-labeled antibodies to CD11c and 201 
CD45, APC-eF780-labeled antibodies to CD4 and CD117, fixable viability dye eFluor 202 
506, and ELISA sets for human IL-8, mouse TNF, IL-4, IL-5, IL-6, IL-13, IL-17, IL25, 203 
IFN and TSLP were purchased from eBioscience. Alternaria alternata extracts were 204 
obtained from Greer Laboratories. 205 
Plasmids have been deposited at the BCCM-GeneCorner plasmid collection (Ghent, 206 
Belgium) and accession numbers are provided for each plasmid. pNFconluc 207 
(LMBP3248), which contains NF-κB-driven luciferase, was a gift from Dr. A. Israël 208 
(Institut Pasteur, Paris, France); pACTβgal (LMBP4341) was from Dr. J. Inoue 209 
(Institute of Medical Sciences, Tokyo, Japan). Mouse ST2 and mouse sIL-1RAcP 210 
were amplified from the mouse macrophage cell line Mf4/4 and cloned into the pEF6-211 
myc/HisA (Invitrogen). Mouse sST2 was PCR amplified from Origene clone 212 
MC204735 and cloned into the pEF6-myc/HisA. pEF-mIL33traps were constructed as 213 
follows. A fragment of mouse sST2 without the signal sequence (amino acids 27-214 
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337), PCR amplified from pEF-msST2, together with a linker sequence of repeating 215 
Gly-Gly-Ser triplets amplified from pCLG-Duba (LMBP6610) were cloned by a 3-way 216 
ligation reaction into the pEF-msIL-1RAcP (amino acids 21-360) vector. The 217 
expression vector for mouse IL-1RAcP (pCR4-Flag-mIL-1RAcP) was kindly provided 218 
by Dr. Sophie Janssens (VIB/University of Ghent, Ghent, Belgium). pEF-BOS-hsST2 219 
and pEF-BOS-hST2 constructs were kindly provided by Prof. Luke O’Neill (Trinity 220 
College Dublin, Ireland). Human sST2 was PCR amplified from pEF-BOS-hsST2; the 221 
human sIL1-RAcP was amplified from a human spleen cDNA library. Both fragments 222 
were cloned into the pEF6-myc/HisA vector. pEF-hIL33traps were constructed as 223 
follows. Human sST2 without the signal sequence (amino acids 19-328) together with 224 
a linker sequence of repeating Gly-Gly-Ser triplets were cloned by a 3-way ligation 225 
reaction into the pEF-hsIL-1RAcP vector. All constructs were confirmed by DNA 226 
sequencing analysis.  227 
Production of recombinant proteins 228 
A truncated construct of mouse IL-33 (residues 109-266), lacking the N-terminus, 229 
with an additional N-terminal hexa-histidine purification tag and a C-terminal 230 
solubilization tag20 was generated and cloned into the pETDuet-1 vector. The vector 231 
was subsequently transformed into E. coli BL21 and expression was induced with 1 232 
mM IPTG followed by overnight incubation at 28°C. The bacterial pellet was 233 
harvested by centrifugation, resolubilized and lysed by sonication. The lysate was 234 
centrifuged and soluble IL-33 was purified from the supernatants by Immobilized 235 
Metal Affinity Chromatography (IMAC) followed by Size Exclusion Chromatography 236 
(SEC), yielding pure and homogenous IL-33 as determined by SDS-PAGE and SEC 237 
(data not shown). 238 
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Murine IL-33trap, sIL-1RAcP and sST2 were produced at the Protein Core of VIB. 239 
Briefly, suspension HEK293 FreeStyle cells in FreeStyle 293 expression medium 240 
were transiently transfected with pEF-msST2 or pEF-mlL-33trap using the 241 
polyethylenimine (PEI) method. 16h after transfection, 20 % of Ex-Cell 293 medium 242 
serum-free was added and the cells were cultured further for 5 days. The secreted 243 
recombinant proteins in the medium fractions were concentrated and diafiltrated 244 
before purification by IMAC. After a final gel-filtration over a Superdex 200 column, 245 
the purified proteins were stored in PBS at -80°C.  246 
Affinity measurements using Isothermal Titration Calorimetry 247 
Experiments were carried out using a VP-ITC instrument (MicroCal) at 37 °C, and 248 
data were analyzed using the Origin ITC analysis software package (recording and 249 
initial analysis), NITPIC (automated baseline corrections)21 and SEDPHAT (fitting and 250 
parameter determination).22 All protein samples were exchanged into the same buffer 251 
(20 mM HEPES, 150 mM NaCl) by size exclusion chromatography. Protein 252 
concentrations were measured spectrophotometrically at 280 nm using calculated 253 
theoretical extinction coefficients and all solutions were extensively degassed before 254 
use. Titrations were always preceded by an initial injection of 3 μl, and were carried 255 
out using 5 μl injections applied 450 s apart. The sample was stirred at a speed of 256 
300 r.p.m. throughout. The thermal titration data were processed21 and fitted using a 257 
‘one binding site’ model,22 and the apparent molar reaction enthalpy (∆H°), apparent 258 
entropy (∆S°), binding affinity (KD) and stoichiometry of binding (N) were determined. 259 
The parameters presented are averages of two (IL-33 vs. sST2) or three (IL-33 vs. 260 
IL-33trap and IL-33trap vs IL-33:sST2) experiments. 261 
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The displacement ITC was set up and performed using the same principles used in 262 
previous studies23 and extensively described by Campoy et al.24 Using the affinity 263 
measured between IL-33 and sST2 (KD,sST2) and the apparent affinity measured in 264 
the displacement ITC between IL-33 ([IL-33]T) and a mix of sST2 ([sST2]T) and IL-265 
33trap (KappD,IL-33trap), the “real” affinity of IL-33 towards IL-33trap (KrealD,IL-33trap) could 266 
be calculated using the following formula:  267 
KrealD,IL-33trap= KappD,IL-33trap/RF with RF=(([sST2]T-[IL-33]T)/KD,sST2)+1 268 
Note that [sST2]T should represent the total amount of active sST2 that can compete 269 
with IL-33trap for IL-33. Since the benchmark ITC between IL-33 and sST2 showed 270 
that only 60% of sST2 is active, we corrected for this deviation by adding  271 
compensating amounts of sST2. For the final calculations we used the concentration 272 
of active sST2, as 60% of the total sST2 in the cell. 273 
IL-33 bioassay 274 
HEK293T, RAW Blue 264.7 cells, immortalized BMDM and HMC-1 human mast cells 275 
were cultured in Dulbecco's modified Eagle's medium, supplemented with 10% fetal 276 
calf serum and 2 mM L-Glutamine. HEK293T cells (human embryonic kidney cells) 277 
were a gift from Dr. Hall (Department of Biochemistry, University of Birmingham, UK). 278 
RAW Blue 264.7 cells were purchased from Invivogen, immortalized bone marrow-279 
derived macrophages (BMDM) were a gift from Dr. Harris (Trinity College Dublin), 280 
HMC-1 cells were a gift from Dr. Lieve Coorevits (KU Leuven, Belgium). For 281 
transfection, HEK293T cells were seeded at 4 × 104 cells/well in 24-well plates and 282 
transiently transfected the next day by calcium phosphate precipitation. For IL-33 283 
neutralization experiments, recombinant IL-33 was pre-incubated for 30 min at room 284 
14 
 
temperature with inhibitors before adding to the cells. Luciferase activity was 285 
measured in the cell lysates 5h later and normalized by β-galactosidase values in 286 
order to correct for potential differences in transfection efficiency. Cytokine profiles in 287 
the cell supernatants were measured 24h later by enzyme-linked immunosorbent 288 
assay (ELISA) according to the manufacturer's protocol. 289 
Animals and IL-33 treatment 290 
C57BL6/J mice were purchased from Janvier. All animal experiments were approved 291 
by the Ethical Committee for Animal Experimentaion of Ghent University – Faculty of 292 
Sciences. Mice were daily i.p. injected with recombinant IL-33trap or sST2 followed 293 
30 min later by 100 ng of recombinant mouse IL-33. Mice were sacrificed on day 6; 294 
peritoneal lavage, spleens and lungs were collected for further analysis. 295 
Analysis of peritoneal lavage, spleens and lung homogenates 296 
Peritoneal lavage was performed using PBS with 0.5% BSA and 2mM EDTA. Cell 297 
populations in peritoneal lavages were quantified by flow cytometry. Multiparameter 298 
analysis was performed on an LSRFortessa (BD) and data were processed using 299 
FlowJo (Tree Star). Dead cells were excluded using the Fixable Viability Dye eFluor 300 
506 (eBioscience). 301 
Spleens were flushed with 2 ml of PBS/0.5% BSA and passed through a 70 m 302 
strainer (Falcon) to generate single cell suspension. Red blood cells were lysed with 303 
1.7 ml ACK lysis buffer (Lonza) for 3 min at room temperature. Splenocytes were re-304 
stimulated ex vivo with 20 ng/ml PMA. Cytokine profiles in the supernatants were 305 
measured 72h later by ELISA. 306 
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Lungs were homogenized with a tissue homogenizer in 320 µl of cold lysis buffer (40 307 
mM Tris-HCl, pH 8.0, 0.275 M NaCl, 20% glycerol [vol/vol], 1 mM PMSF, 1 mM 308 
sodium orthovanadate [Na3VO4], 10 mM NaF, 1 g/ml aprotinin, and 1 g/ml 309 
leupeptin) using a tissue homogenizer (IKA) with the addition of 2% Igepal after 310 
homogenization. Samples were then rotated for 20 min at 4ºC with agitation, followed 311 
by a centrifugation to pellet debris. Cleared lysate was quantified for protein 312 
concentration using the Bradford Bio-Rad protein assay. IL-5 concentrations in the 313 
supernatants were measured by ELISA and corrected for total protein content. 314 
Alternaria alternata-induced asthma model 315 
Mice were anesthetized with isoflurane and received 5 µg Alternaria alternata i.t. 316 
Seven days later, mice were challenged i.t. with 20 µg Alternaria alternata for 3 days 317 
as indicated in Figure 5C under anesthesia. IL-33 was blocked by i.t. injection of 318 
recombinant IL-33trap at the time of challenge. Mice were sacrificed 1 day after the 319 
last challenge. BAL was performed using 3x1 ml EDTA-containing PBS and analyzed 320 
using flow cytometry. For staining of ILC2 and regulatory T cells, lungs were cut into 321 
small pieces and incubated at 37°C for 30 minutes in RPMI 1640 containing Liberase 322 
TM (Roche) and DNase I (Roche). Lungs were filtered over a 70μm strainer (Falcon) 323 
and red blood cells were lysed with 1 ml ACK lysis buffer (Lonza) for 3 min at room 324 
temperature before being stained with different FACS antibodies. Lungs were snap-325 
frozen in liquid nitrogen and kept at −80°C until further processing for real-time 326 
quantitative RT-PCR (qRT-PCR) or cytokine measurements by ELISA. RNA was 327 
obtained using the TriPure Isolation Reagent (Roche, Mannheim, Germany) and 328 
isolated according to the manufacturer's instructions. RNA was reverse transcribed 329 
with a  iScript™ Advanced cDNA Synthesis Kit (Bio-Rad), and samples were 330 
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analyzed by SYBR green-based qRT-PCR with a LightCycler 480 system (Roche) 331 
against reference genes (Actin, Hprt, and Sdha). Airway hyperreactivity (AHR) was 332 
analyzed 24 h after the last Alternaria alternata challenge using  flexiVent  invasive  333 
measurement  of  dynamic  resistance (SCIREQ, Montreal, Quebec, Canada).  Mice  334 
were  anesthetized  with  urethane and paralyzed using d-tubocurarine,  followed by 335 
mechanical ventilation through a cannula in the trachea. Increasing concentrations of 336 
methacholine (25 mg/ml – 800 mg/ml) were nebulized using Aeroneb (SCIREQ). 337 
Dynamic resistance was recorded  after  a  standardized  inhalation  maneuver  given  338 
every  10  s  for  2  min.  Baseline  resistance was restored  before  administering  the  339 
subsequent  doses of  methacholine.  340 
Statistical analyses  341 
The results are expressed as mean ± SE. Statistical significance between groups 342 
was calculated using 1-way ANOVA, followed by Fischer’s Least Significant 343 
Difference test with GraphPad Prism software (v7.01; GraphPad Software, La Jolla, 344 
Calif). Differences between groups were considered significant when the p-value was 345 









Design and production of recombinant IL-33trap as a monomeric high affinity 353 
IL-33 antagonist 354 
The cornerstone for the assembly of a signaling complex mediated by IL-33 is an 355 
encounter binary complex with its cognate receptor ST2, which subsequently primes 356 
recruitment of the IL-1RAcP co-receptor to establish a tripartite high affinity signaling 357 
complex11 (Figure 1A). This mechanistic principle was the basis for our strategy to 358 
engineer a recombinant fusion protein (hereafter referred to as “IL-33trap”) 359 
comprising the soluble extracellular part of mouse IL-1RAcP N-terminally fused to the 360 
soluble extracellular part of mouse ST2 via a flexible GGS (glycine-glycine-serine) 361 
linker (Figure 1A). The expression construct encodes for the IL-1RAcP signal 362 
sequence (ss) at the N-terminus, which allows protein secretion, and a myc/His tag at 363 
the C-terminus to facilitate protein purification and detection. We have opted to 364 
produce the IL-33trap in HEK293 FreeStyle cells to ensure proper folding as well as 365 
correct processing and presentation of N-linked glycosylation, and purified the 366 
recombinant protein from conditioned media using affinity chromatography and size-367 
exclusion chromatography (Figure 1B). In parallel, we also generated and purified 368 
recombinant sST2. Treatment of IL-33trap and sST2 with Peptide:N-Glycosidase F 369 
(PNGase F), an endoglycosidase that specifically removes N-linked glycans from 370 
glycoproteins, showed that sST2 and IL-33trap are both glycosylated (Figure 1B). 371 
In the first instance, we sought to carry out binding studies by isothermal titration 372 
calorimetry (ITC) to determine and compare the affinity of IL-33 towards sST2 and 373 
the IL-33trap. Benchmarking of the affinity of IL-33 to sST2 revealed a moderately 374 
strong exothermic binding event and an equilibrium dissociation constant (KD) of 4.59 375 
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nM (Figure 1C) consistent with affinities determined by orthogonal methods.25 376 
Consistent with the working mechanistic signaling model for the receptor complex 377 
mediated by IL-33, the latter only displayed a measurable affinity towards IL-1RAcP 378 
in the presence of sST2 (data not shown), confirming the expected functionality of 379 
both receptor modalities. Direct titration of IL-33 to the IL-33trap, encompassing both 380 
receptor subunits, suggested an ultrahigh affinity with a KD value in the picomolar 381 
range (Figure 1D). Given the limitations of deriving reliable KD values from such 382 
steep binding isotherms (Wiseman C-value > 1000),26 we resorted to displacement 383 
ITC.23, 27 This experiment revealed an average apparent KD of 8.14 nM, from which 384 
the actual KD of IL-33 towards the IL-33trap was calculated as 0.150 nM. Thus, the 385 
IL-33trap displays ultrahigh affinity towards IL-33 that is ~30-fold higher than the 386 
affinity of sST2 for IL-33 (Figure 1E). 387 
 388 
IL-33trap specifically inhibits IL-33 signaling in vitro 389 
To test if the IL-33trap displays antagonistic properties, we investigated its ability to 390 
inhibit IL-33 signaling in a cellular assay. sST2 was used as a positive control. 391 
HEK293T cells were made responsive to IL-33 by transfection with ST2 and IL-392 
1RAcP, and IL-33-induced NF-B activation was followed via NF-B dependent 393 
luciferase reporter gene expression as a read-out. IL-33 treatment resulted in robust 394 
NF-B activation, which was inhibited by pre-incubation of IL-33 with sST2 or IL-395 
33trap (Figure 2A). The relative inhibitory potency of sST2 and IL-33trap is analyzed 396 
in more detail below. To eliminate the possibility that our IL-33trap might interfere 397 
with IL-1 or IL-18, or IL-36, all of which bind different core receptors but utilize IL-398 
1RAcP and IL-1RAcP-related co-receptors, we established similar NF-B dependent 399 
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reporter assays and confirmed that the IL-33trap uniquely targets IL-33 signaling 400 
(Figure 2A). The above described experiments were all performed with mouse IL-33 401 
and mouse IL33trap. To analyze the effect of its human counterparts, we also 402 
constructed human IL-33trap and tested its ability to inhibit NF-B signaling initiated 403 
by human IL-33. Similarly to mouse IL33trap, human IL-33trap as well as human 404 
sST2 efficiently neutralized human IL-33 (Figure 2B). We also tested the impact of 405 
the GGS repeat linker length on the ability of IL-33trap to inhibit IL-33-induced NF-B 406 
activity. However, mouse IL-33traps with a linker of 8- (used in further 407 
experiments),12- or 20-GGS repeats were equally effective, while a linker length of 408 
20-GGS repeats seemed to be preferred in the case of human IL-33trap (Figure 2C).  409 
 410 
IL-33trap is a much more potent IL-33 inhibitor in vitro than sST2  411 
For a functional comparison, sST2 and IL-33 trap were tested at equimolar levels for 412 
their IL-33 inhibiting potential in a cell-based bio-assay. To this end, we pre-incubated 413 
recombinant IL-33 with equimolar concentrations of either sST2 or IL-33trap over a 414 
range of inhibitor-to-target ratios and assessed the residual IL-33 activity in our 415 
HEK293T cellular assay. IL-33trap exhibited dramatically enhanced ability to inhibit 416 
IL-33 at each tested concentration when compared to sST2 (Figure 3A). Strikingly, 417 
the IL-33trap was able to potently inhibit IL-33 activity already at a molar ratio of 1:1 418 
(inhibitor to IL-33), while sST2 failed to have any significant effect at this 419 
concentration. As can be calculated from the concentration response curve, the 420 
concentration of IL-33trap that provides 90% inhibition is almost 27 times lower than 421 
that of sST2 (IC90 1.04 nM vs 27.98 nM; Figure 3B). Also the combination of sST2 422 
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and sIL-1RAcP was less potent than IL-33trap (IC90 1.04 nM vs 8.92 nM). As 423 
expected, sIL-1RAcP alone was not able to neutralize IL-33 activity (Figure 3B). 424 
Next, to investigate the inhibitory potential of IL-33trap at endogenous receptor 425 
expression levels, we examined the response of mouse macrophages or human 426 
mast cells to IL-33 in terms of enhanced cytokine production. Consistent with the 427 
HEK293T assay, IL-33trap was a dramatically more potent blocker of IL-33 activity, 428 
as measured by IL-33-induced TNF, IL-6 or IL-8 cytokine and chemokine production 429 
from RAW 264.7 and immortalized BMDM or HMC-1 mast cells, respectively (Figure 430 
3C). Collectively, our data shows that a novel IL-33 inhibitor, IL-33trap, exhibits 431 
significantly improved ability to neutralize IL-33 compared to sST2. 432 
 433 
IL-33 trap inhibits IL-33 in vivo  434 
We next explored whether the observed potency of the IL-33trap in vitro could be 435 
extrapolated to a neutralization of IL-33 activity in vivo. It has been previously shown 436 
that intraperitoneal (i.p.) IL-33 injection induces increased eosinophil infiltration to the 437 
peritoneal cavity, splenomegaly and pro-inflammatory cytokine production in lungs.7, 438 
11 Therefore, C57BL/6J mice were injected i.p. for five consecutive days with either 439 
PBS, sST2 or IL-33trap followed by IL-33 injection 30 minutes later. Consistent with 440 
previous reports, injection of IL-33 dramatically induced eosinophil infiltration, which 441 
was completely inhibited by IL-33trap already at a 20:1 ratio of inhibitor to IL-33 442 
(Figure 4A). At the same time sST2 showed only a minimal ability to reduce 443 
eosinophilia at the same molar ratio, and could only partially reduce eosinophil 444 
infiltration at 40-fold molar excess over IL-33 (Figure 4A). Similarly, IL-5 production 445 
induced by IL-33 in the lungs and splenomegaly were completely inhibited by the IL-446 
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33trap, while sST2 was only able to partially inhibit these responses (Figure 4B and 447 
C). Finally, we isolated splenocytes and assayed pro-inflammatory cytokine 448 
production in response to in vitro PMA re-stimulation. In line with the other readouts, 449 
splenocytes derived from mice injected with IL-33 produced increased amounts of 450 
signature IL-33-induced cytokines, IL-5 and IL-13 (Figure 4D). This response was 451 
completely blunted when mice were pre-treated with IL-33trap, while sST2 had little 452 
effect. To rule out the possibility that IL-33trap or sST2 preparations have 453 
contaminants that might affect the inflammatory response, we also injected mice with 454 
inhibitors in the absence of IL-33. Neither IL-33trap nor sST2 alone induced any 455 
significant increase in the measured inflammatory responses (Figure 4A-D). 456 
Collectively, these data show that the ability of the novel IL-33trap inhibitor to 457 
neutralize IL-33 activity in vivo is superior to that of sST2.  458 
 459 
IL-33trap attenuates inflammatory responses in a mouse model of acute 460 
allergic airway inflammation 461 
The pathological role of IL-33 is most firmly established in the case of asthma, 462 
supported by a large body of experimental data.28 Therefore, we set out to investigate 463 
whether IL-33trap can reduce allergic responses in a mouse model of acute allergic 464 
airway inflammation. First, to determine the optimal route of IL-33trap delivery, we 465 
administered IL-33trap for 3 days either i.p., intravenously (i.v.) or intratracheally (i.t), 466 
followed by i.t. administration of IL-33 three hours later, after which inflammatory cell 467 
infiltration in the lungs was measured by flow cytometry. As can be seen from Figure 468 
5A, the numbers of ILC2 or eosinophils in lungs were significantly increased in mice 469 
treated with IL-33, while pre-treatment with IL-33trap efficiently inhibited the 470 
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inflammatory response, regardless of the administration route. Since local pulmonary 471 
drug delivery has significant advantages to the human patients, being less invasive 472 
than injections and minimizing the systemic side effects, we further concentrated on 473 
the i.t. route of IL-33trap administration. 474 
The fungus Alternaria alternata is known to be a significant source of aeroallergens 475 
and an important risk factor for the development of asthma. Alternaria alternata-476 
specific serine protease activity has been shown to cause the rapid release of IL-33 477 
into the airways of mice, which triggers Th2 inflammation and loss of lung function.29 478 
In contrast, IL-33 release was not detectable upon exposure to another common 479 
allergen, house-dust mite (HDM). In agreement, we also showed that intratracheal 480 
treatment with Alternaria alternata extract induced a robust release of IL-33, while 481 
HDM had no clear effect (Figure 5B). Moreover, other epithelial-derived cytokines, 482 
TSLP and IL-25, remained undetectable (Figure 5B). Alternaria alternata was 483 
therefore found to be the most appropriate mouse model to test the effect of the IL-484 
33trap on the development of allergic asthma.  485 
C57BL/6 mice were sensitized i.t. with a low dose of Alternaria alternata, followed by 486 
i.t. challenge with high dose of Alternaria alternata either alone or together with IL-487 
33trap on days 7-9 post sensitization (Figure 5C). The next day, the presence of 488 
inflammatory cells in the bronchoalveolar lavage (BAL) fluid was analyzed by flow 489 
cytometry (Figure 5D, left panel). As expected, Alternaria alternata-treated mice 490 
developed signs of allergic airway inflammation, as evaluated by increased numbers 491 
of lymphocytes, dendritic cells and eosinophils in the BAL (Figure 5D). However, BAL 492 
eosinophilia and lymphocytosis, as well as increased DC numbers, were significantly 493 
inhibited by IL-33trap, showing the therapeutic potential of this inhibitor when given at 494 
23 
 
the time of allergen challenge. Similarly, Alternaria alternata exposure increased 495 
ILC2, signature IL-33-responsive cells and important drivers of IL-5/IL-13 496 
inflammatory responses, in lung tissue, which was significantly reduced in the 497 
presence of IL-33trap (Figure 5D, right panel). IL-33 administration has previously 498 
been shown to increase the number of lung regulatory T cells (Treg), which exhibited 499 
“Th2-like” characteristics and lost their inhibitory capacities, thus possibly further 500 
contributing to Th2-type inflammation.30 We similarly detected an increase in lung 501 
Treg levels upon Alternaria alternata exposure, which was prevented by IL-33trap 502 
(Figure 5D, right panel).  503 
Furthermore, increased levels of Th2 cytokines associated with asthma, such as IL-4, 504 
IL-5 and IL-13, in the lung homogenates were also blunted by IL-33 trap (Figure 5E). 505 
Although our treatment protocol predominantly induced Th2-type responses, we also 506 
detected some increase in IL-17 and IFN- upon Alternaria alternata exposure, which 507 
was inhibited by IL-33trap, while the levels of epithelial-derived cytokines TSLP and 508 
IL-25 remained unchanged (Figure 5E).  509 
IL-13 is a main driver of goblet cell metaplasia, which is characterized by increased 510 
production of MUC5AC, SPDEF and AGR2.31 In our model, Alternaria alternata 511 
challenge increased lung mRNA expression of all these genes, which was strongly 512 
reduced upon IL-33trap treatment (Figure 5F). Finally, Alternaria alternata-induced 513 
AHR to metacholine was also reduced upon IL-33trap treatment (Figure 5G).  514 
To analyze if IL-33trap can also inhibit already established inflammation, we 515 
sensitized and challenged mice with Alternaria alternata as described above, after 516 
which we re-challenged them 3 days later with Alternaria alternata either alone or 517 
together with IL-33trap (Figure 5H). However, in this setting IL-33trap was unable to 518 
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inhibit BAL eosinophilia and lung Muc5ac mRNA production (Figure 5I), suggesting 519 
that IL-33 plays a more important role at the initiation of allergic airway inflammation. 520 
Collectively, these data provide clear evidence for the ability of IL-33trap to inhibit the 521 
early development of allergic airway inflammation and subsequently suppress key 522 
pathological manifestations of asthma, including inflammation, goblet cell metaplasia 523 


















Recent advances in our understanding of the role of IL-33 in asthma and other 540 
allergic diseases such as atopic dermatitis has attracted much attention to IL-33 as a 541 
novel therapeutic target. A number of IL-33 targeting biologics are in clinical 542 
development (Phase 1 or 2) for asthma and other allergic diseaes. Two are 543 
monoclonal antibodies against ST2 (RG6149, formerly AMG282, Genentech; 544 
CNTO7160, GSK), and two others are monoclonal antibodies directly binding IL-33 545 
(ANB020, AnaptysBio; REGN3500, Regeneron). However, although monoclonal 546 
antibodies are considered to be more efficient than soluble recombinant receptor 547 
molecules due to their pharmacokinetic properties, antibodies are inherently 548 
immunogenic and there is a potential for patients to develop anti-drug antibodies 549 
(ADA) over time, resulting in loss of clinical response.32, 33, 34 Of interest, a single 550 
cross-sectional study showed ADA development and lower efficacy outcomes in a 551 
higher proportion of patients with rheumatoid arthritis receiving an anti-TNF 552 
monoclonal antibody (adalimumab or infliximab) than in patients receiving a soluble 553 
dimeric TNF receptor fusion protein (etanercept).35 Since the IL-33trap sequence is 554 
based on naturally occuring receptor sequences, immunogenicity is expected to be 555 
lower than in the case of antibodies targeting IL-33 or its receptor. Therefore, our IL-556 
33trap might be an attractive alternative to antibodies in case of ADA development. 557 
Furthermore, the absence of an Fc fragment in IL-33trap would avoid non-specific 558 
binding to Fc receptors and Fc-associated effector functions. Also, being receptor-559 
based, IL-33trap can be expected to bind all active variants of IL-33, such as splice 560 
variants and IL-33 processing products that have been described,36, 37, 38 some of 561 
which may lack the epitope recognized by monoclonal antibodies. IL-33 has also 562 
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been described to be rapidly inactivated by oxidation of critical cysteine residues.39 In 563 
this context, oxidized IL-33 will still bind most anti-IL-33 monoclonal antibodies and 564 
thus serve as a sink, reducing their efficiency. As oxidized IL-33 no longer binds ST2, 565 
such a an effect is unlikely to happen in case of IL-33trap. Similarly, the endogenous 566 
sST2 decoy receptor may serve as a sink for anti-ST2 antibodies, but not for IL-567 
33trap. Moreover, as elevated serum sST2 levels in asthma and other inflammatory 568 
conditions are believed to exert an important regulatory role,40, 41, 42 it is better not to 569 
interfere with its normal homeostatic function. 570 
In general, soluble receptor-based biologics have proven to be valuable alternatives 571 
for monoclonal antibodies. This is well illustrated by the TNF antagonist etanercept, 572 
the CD80/86 antagonist abatacept and the IL-1 antagonist rilonacept.43 In all cases, 573 
soluble receptors were engineered to encode an IgG Fc region to increase half-life 574 
and to permit dimerization and high affinity ligand binding. The monomeric nature and 575 
the use of a flexible linker in the design of our IL-33trap, circumventing the need for 576 
Fc fusion and production of two different recombinant proteins, offers a significant 577 
improvement in terms of manufacturing costs and possible undesired Fc-associated 578 
side effects. For future translational studies, it will however be most favorable to 579 
increase the half-life of the IL-33trap protein. The size of the IL-33trap molecule (~90 580 
kDa for the non-glycosylated form) is above the renal filtration cut-off, but engineering 581 
FcRn recycling into the trap molecule by genetic fusion to serum albumin or serum 582 
albumin-binding moieties may be envisioned.44 Furthermore, reducing the 583 
glycosylation complexity and heterogeneity of IL-33trap might also have an impact on 584 




In conclusion, our data demonstrate that IL-33trap has great potential and can be 587 
considered a breakthrough technology for the development of new biologics against 588 
asthma and other allergic diseases. It must be mentioned that we were not able to 589 
show a protective effect of IL-33trap when given to mice with established allergic 590 
airway inflammation, as we show in figure 5 (panel H and I) that the IL-33trap has no 591 
effect on eosinophilia and Muc5a expression in the lung when analyzed in the re-592 
challenge model. Therefore, it can be expected that also AHR and airway remodeling 593 
will not be inhibited (the opposite would not necessarily be true). These results are 594 
consistent with previously published data showing that combinatorial inhibition of IL-595 
33, IL-25 and TSLP by monoclonal antibodies was incapable of inhibiting established 596 
chronic airway inflammation, but was effective at early stages of the disease.45 These 597 
data suggest that at later stages of disease, Th2 responses can bypass the IL-33 598 
axis. Of interest, combined blockade of the IL-13 and IL-33 pathways was recently 599 
shown to lead to a greater inhibition of type 2 inflammation over inhibition of either 600 
pathway alone,46 supporting the idea that combinatiorial treatment approaches may 601 
yield additional efficacy over single-axis therapies alone. In this regard, also other 602 
cytokine trap proteins, such as the recently described TSLPtrap,47 may be interesting 603 
leads. The IL-33/ST2 axis has also been implicated in various other, non-Th2, 604 
diseases such as rheumatoid arthritis, colitis, multiple sclerosis, lupus, age-related 605 
macular degeneration, fibrosis, and disorders of the central nervous system,4,48 606 
implicating that the impact of our IL-33trap technology may be much broader than 607 
allergic diseases. Given the apparent diverse roles of IL-33 in a multitude of 608 
processes, manipulation of IL-33 signaling may be highly disease dependent. Of 609 
note, as there is evidence that the IL-33/ST2 system also participates in tissue repair 610 
and (dys)regulates regulatory T cells in certain conditions,30, 49, 50 several questions 611 
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and challenges remain. A better understanding of the impact of IL-33 and sST2 612 
during disease and how IL-33/ST2 targeting could affect different organ systems will 613 
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Figure Legends 854 
Figure 1. IL-33trap exhibits enhanced ligand binding affinity 855 
(A) Schematic representation of the IL-33 receptor complex and the IL-33trap design. 856 
The signal peptide at the N-terminus ensures secretion of the expressed protein into 857 
the medium fraction, while a carboxy terminal myc/His6 tag is used for detection and 858 
purification. (B) sST2 and IL-33trap were subjected to PNGase F treatment and 859 
analyzed by SDS-PAGE and Coomassie blue staining. Recombinant PNGase F is 860 
marked with an asterisk. (C) ITC titration of IL-33 (37.17 μM in syringe) to sST2 (3.37 861 
μM in cell) at 37°C with Wiseman C-value of 925 (<1000). (D) ITC titration of IL-33 862 
(14.23 μM in syringe) to IL-33trap (1.20 μM in cell) at 37°C with Wiseman C-value of 863 
3750 (>1000). (E) Displacement ITC of IL-33trap (20.30 μM in syringe) to IL-33 (1.75 864 
μM in cell) in competition with sST2 (3.37 μM in cell) at 37°C with Wiseman C-value 865 
of 214 (<1000). A schematic reaction is shown within the thermogram plot. Binding 866 
parameters were determined by SEDPHAT and manually averaged over two (C)) or 867 
three (D and E) experiments. In addition, manually calculated values for the Gibbs 868 
free energy (ΔG) and entropic component (-TΔS) of the reactions are displayed. 869 
 870 
Figure 2. IL-33trap specifically inhibits IL-33 activity 871 
(A) HEK293T cells were transfected with NF-B reporter plasmid and the expression 872 
plasmids for the indicated receptor complexes. Cells were treated with 10 ng/ml of 873 
recombinant IL-1, IL-33, IL-36 or IL-18 that were pre-incubated with 500 ng/ml of 874 
IL-33trap or sST2. Luciferase activity in cell lysates was measured 5h later. (B) 875 
HEK293T cells were transfected with NF-B reporter plasmid and the human IL-33 876 
receptor complex expression plasmids. Cells were treated with recombinant human 877 
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IL-33 that was pre-incubated with human IL-33trap or sST2 (note that non-equimolar 878 
concentrations were used). Luciferase activity in cell lysates was measured 5h later. 879 
(C) HEK293T cells were treated as in B. Mouse (left panel) or human (right panel) IL-880 
33trap constructs with different linker length or sST2 were used to neutralize IL-33 as 881 
indicated. Values represent the mean of triplicates ± SE. 882 
 883 
Figure 3. IL-33trap is a more potent IL-33 inhibitor than sST2 in vitro 884 
(A-B). HEK293T cells were transfected with NF-B reporter plasmid and the IL-33 885 
receptor complex expression plasmids. Cells were treated with recombinant IL-33 886 
that was pre-incubated with the indicated molar excess of IL-33trap or sST2. 887 
Luciferase activity in cell lysates was measured 5h later (A). Concentration response 888 
curves, IC50 and IC90 were calculated (B). (C) RAW 264.7, immortalized BMDM and 889 
HMC-1 cells were treated with recombinant IL-33 that was pre-incubated with the 890 
indicated concentrations of IL-33trap or sST2. Cytokine concentrations in the 891 
supernatants were measured by ELISA 24h later. Values represent the mean of 892 
triplicates ± SE.  893 
 894 
Figure 4. IL-33trap is a more potent IL-33 inhibitor than sST2 in vivo 895 
C57BL/6 mice (5 mice per group) were injected i.p. for 5 consecutive days with PBS, 896 
IL-33trap or sST2 followed by i.p. injection of 100 ng IL-33 30 min later, as indicated. 897 
Mice were sacrificed 24h after the last injection. (A) Individual cell types in the 898 
peritoneal lavage were identified by flow cytometry. Representative FACS plots 899 
showing identification of Siglec F+CD11bInt eosinophils (left). Cells were pre-gated as 900 
single live CD3−CD19−Ly6G− and were SSCHi. Numbers represent eosinophils as a 901 
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percentage of live cells (right). (B) IL-5 concentration in the lung homogenates was 902 
measured by ELISA and expressed per mg of protein. (C) Spleen weight at the end 903 
of the experiment for each group is shown. (D) Splenocytes were re-stimulated ex 904 
vivo with 20 ng/ml PMA. IL-5 and IL-13 concentrations in the supernatants were 905 
determined 72h later by ELISA. Results are representative of two independent 906 
experiments. Error bars represent the mean ± SE. Significance levels: ns P > 0.05, 907 
**P < 0.01, and ***P < 0.001. 908 
 909 
Figure 5. IL-33trap inhibits the development of Alternaria alternata-induced 910 
asthma 911 
(A) Experimental set up (left). C57BL/6J mice (n=5) were injected as indicated. ILC2 912 
and eosinophils were determined in the lungs on day 4 by flow cytometry (right). (B) 913 
Mice were injected with Alternaria alternata or HDM and concentration of IL-33 in the 914 
BAL was measured by ELISA 1h later (left). Alternatively, mice were injected with 915 
10g Alternaria alternata and cytokine concentrations in the BAL were measured 916 
(right). (C) Experimental set up for the Alternaria alternata-induced model. (D) Airway 917 
inflammation was induced as depicted in C (n=8). Individual cell types in the BAL and 918 
lung tissue were identified by flow cytometry. (E) Cytokine concentrations in lung 919 
homogenate were measured by ELISA. (F) Gene expression in lung was measured 920 
by RT-PCR. (G) AHR was measured after exposure to increasing concentrations of 921 
metacholine. (H) Experimental set up for the established Alternaria alternata-induced 922 
asthma. (I) Airway inflammation was induced as depicted in H (n=8). Eosinophils in 923 
the BAL were identified by flow cytometry and expression of Muc5ac was measured 924 
by RT-PCR. Results are representative of two independent experiments. Error bars 925 
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